A Cohort Establishment Study of Total Management of Ovarian Cancer

Recruiting

• Conditions: Tumor of Female Reproductive System; Ovarian Cancer

• Registration Number: NCT06018935
• Lead Sponsor: Sichuan Cancer Hospital and Research Institute

Brief Summary

A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Detailed Description

1. To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer);

2. To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures;

3. The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed;

4. To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Study Timeline

• Study First Submitted: 2023-08-10
• Study First Submitted QC: 2023-08-30
• Study First Posted: 2023-08-31
• Status Verified: 2024-06
• Study Start: 2024-06-17
• Last Update Submitted: 2024-06-17
• Last Update Posted: 2024-06-20
• Primary Completion: 2025-09-01
• Study Completion: 2025-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 500

Inclusion Criteria

1. Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;
2. Can cooperate with later follow-up.

Exclusion Criteria

1. Patients with other malignant tumors or previous history of other malignant tumors;
2. Have cognitive impairment.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progress Freesurvival (PFS)	Average six months after study completion.	The time from the start of treatment until the patient progresses further or dies.
Overall Survival (OS)	Average six months after study completion.	Measure the time from the start of treatment to the time of death.

Secondary Outcome Measures

Name	Time	Method
Occurrence of adverse reactions	Average six months after study completion.	All adverse events were recorded.

Trial Locations

Locations (1)

Sichuan Cancer Hospital; 🇨🇳 Chengdu, China